
Exacerbations of hepatitis during and after discontinuation of entecavir therapy have also been reported.
Cases of lactic acidosis have been reported, often in association with hepatic decompensation, other serious medical conditions or drug exposures.
Treatment beyond 48 weeks: Continued treatment with entecavir for a median duration of 96 weeks did not reveal any new safety signals.
View ADR Reporting Link